Abstract
Aldose Reductase (ALR2) is defined as the first enzyme of the “polyol pathway”. As such, ALR2 would convert glucose to sorbitol through an NADPH dependent reaction. Considered a promoter of osmotic imbalance under hyperglycemic conditions, the enzyme has been under intense investigation as a critical target to prevent and control diabetic complications through the inhibition of its activity. Further characterization of ALR2 suggests its participation in cell detoxification mechanisms through the reduction of toxic aldehydes. Moreover, intriguing is the apparent involvement of the enzyme in the signalling machinery of inflammatory cell response. Here, the structural and functional assessment of ALR2 as an aldose/aldehyde reducing enzyme, and its involvement in various aspects of cell function from sugar metabolism to redox homeostasis and cell signaling are presented.
Keywords: Aldose reductase, polyol pathway
Current Medicinal Chemistry
Title: From a Dull Enzyme to Something Else: Facts and Perspectives Regarding Aldose Reductase
Volume: 15 Issue: 15
Author(s): A. Del Corso, M. Cappiello and U. Mura
Affiliation:
Keywords: Aldose reductase, polyol pathway
Abstract: Aldose Reductase (ALR2) is defined as the first enzyme of the “polyol pathway”. As such, ALR2 would convert glucose to sorbitol through an NADPH dependent reaction. Considered a promoter of osmotic imbalance under hyperglycemic conditions, the enzyme has been under intense investigation as a critical target to prevent and control diabetic complications through the inhibition of its activity. Further characterization of ALR2 suggests its participation in cell detoxification mechanisms through the reduction of toxic aldehydes. Moreover, intriguing is the apparent involvement of the enzyme in the signalling machinery of inflammatory cell response. Here, the structural and functional assessment of ALR2 as an aldose/aldehyde reducing enzyme, and its involvement in various aspects of cell function from sugar metabolism to redox homeostasis and cell signaling are presented.
Export Options
About this article
Cite this article as:
Corso Del A., Cappiello M. and Mura U., From a Dull Enzyme to Something Else: Facts and Perspectives Regarding Aldose Reductase, Current Medicinal Chemistry 2008; 15 (15) . https://dx.doi.org/10.2174/092986708784638870
DOI https://dx.doi.org/10.2174/092986708784638870 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Reviewing Biochemical Implications of Normal and Mutated Huntingtin in Huntington’s Disease
Current Medicinal Chemistry Atorvastatin and Diabetic Vascular Complications
Current Pharmaceutical Design Green Synthesis of Phosphoryl-2-Oxo-2H-Pyran via Three Component Reaction of Trialkyl Phosphites
Combinatorial Chemistry & High Throughput Screening Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Exercise and Postprandial Glycemic Control in Type 2 Diabetes
Current Diabetes Reviews Clinical Applications of Myostatin Inhibitors for Neuromuscular Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Neuroprotection for Amyotrophic Lateral Sclerosis: Role of Stem Cells, Growth Factors, and Gene Therapy
Central Nervous System Agents in Medicinal Chemistry Gene Therapy in Peripheral Nerve Reconstruction Approaches
Current Gene Therapy Exploiting Substrate Recognition for Selective Inhibition of Protein Kinases
Current Pharmaceutical Design Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options
Current Neuropharmacology Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Gene Therapy for the Peripheral Nervous System: A Strategy to Repair the Injured Nerve?
Current Gene Therapy Molecular Insights and Therapeutic Targets in Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry The Proteasome in Health and Disease
Current Pharmaceutical Design The Unbiased Search of Biomarkers in Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease
Current Pharmaceutical Design Mediterranean Diet, Brain and Muscle: Olive Polyphenols and Resveratrol Protection in Neurodegenerative and Neuromuscular Disorders
Current Medicinal Chemistry Non Enzymatic Glycated Proteins in the Blood and Cardiovascular Disease
Current Pharmaceutical Design